The objective of this study was to correlate the expression of topoisomerase (topo) IIα to in vitro drug sensitivity and to the clinical outcome in patients with acute leukaemia. Leukaemic cells were isolated from bone marrow or blood from 94 patients. Topo IIα mRNA (n=58) and protein (n=60) expression was determined by real-time RT-PCR and flow cytometry, respectively. In both groups, chemosensitivity testing by a bioluminescence ATP assay was performed to a variable extent for both topo IIα poisons and non-topo IIα targeting drugs. Topo IIα mRNA expression varied with relative values ranging from 0.03 to 14.20 (median 1.10). The median value for topo IIα protein-positive cells was 23% (range 0-99%). Cell samples from patients with a high (>median value) percentage of topo IIα-positive cells were significantly more sensitive to the topo IIα active drugs etoposide and daunorubicin, and showed a borderline value for idarubicin (p=0.08), while there was no difference for non-topo IIα targeting drugs. However, we did not find any significant differences in mRNA expression or the percentage of topo IIα-positive cells in patients who achieved complete remission after at most two induction courses compared with those who did not, nor did we find any difference in survival when patients with high mRNA expression/percentage of topo IIα-positive cells were compared with patients with low values. We conclude that expression of topo IIα, determined as percentage of topo IIα-positive cells, in leukaemic cells correlates to chemosensitivity in vitro against topoisomerase poisons but that it does not predict clinical outcome in acute leukaemia.

Related Articles